TP53 and neoplasm: In patients treated with ICI (HD-ICI cohort), PFS and OS differed between patient groups defined by mutation status (p = 0.017 and p = 0.014, respectively) and the best clinical outcome was observed in patients with KRAS and TP53 co-mutated tumours (Fig. 1a, b).